Therapy for Movement Disorders

Total Page:16

File Type:pdf, Size:1020Kb

Therapy for Movement Disorders Cynthia Comella, MD, FAAN Rush University Medical Center Chicago, IL TREATMENT OF MOTOR SYMPTOMS IN PARKINSON DISEASE Disclosures . Compensation/honoraria for services as a consultant or an advisory committee member: Acadia, Aeon, Allergan, Inc; Impax Pharmaceuticals; Ipsen Biopharmaceuticals, Inc; Medtronic Inc.; Merz Pharmaceuticals; Neurocrine. Royalties: Cambridge, Humana Press; Wolters Kluwer Objectives Treatment of PD . Available treatments for motor PD Treatment of motor symptoms Treatment of motor complications Motor fluctuations Dyskinesia . Overview new therapies in clinical trial Not my objectives Before I came here I was confused about this subject. Having listened to your lecture I am still confused. But on a higher level. Enrico Fermi PD motor symptoms: Therapeutic targets Oertel W, Shulz JB. J Neurochem 2016 . No effective neuroprotective agent . Monotherapy (Efficacious) Levodopa Dopamine agonists: (pramipexole, ropinirole, rotigotine) MAO-B inhibitors: (selegiline, rasagiline) Amantadine (likely) . Motor fluctuations (Efficacious) Efficacious: Dopamine agonists (pramipexole, ropinirole, rotigotine, apomorphine) Levodopa gel intestinal infusions COMT inhibitors (entacapone, tolcapone, opicapone) MAO-B inhibitors (rasagiline, safinamide) Zonisamide Bilateral STN and GPi stimulation . Dyskinesia (Efficacious) Intestinal infusions Amantadine Bilateral STN and GPi stimulation clozapine Fox et al. Mov Disord March 2018 Modest benefit . MAO-B inhibitors (selegiline, rasagiline, safinamide) Modest benefit Not neuroprotective Used for motor fluctuations (extends half life LD) . Anticholinergics May help tremor rigidity, not bradykinesia Many side effects Largely reserved for young subjects . Amantadine Most used for treatment of dyskinesia affects dopamine, acetylcholine and glutamate Mild improvement for PD symptoms Renal clearance (care with elderly or kidney disease) Levodopa . Gold standard for 50 years . Efficacious as monotherapy treatment for PD symptoms . No evidence for enhanced disease progression Levodopa: Common misconceptions of patients . If I take levodopa now, I will develop tolerance to it in the future . I am afraid to start levodopa because I will use up the “good time” . I should only take medication when I find it impossible to carry out my life . Levodopa will cause faster progression of my PD Levodopa in early, untreated PD ELDOPA study PSG. NEJM 2004; 351:2498-2508 . 445 with PD diagnosis within 2 years . Untreated . Randomized: Oral levodopa 100 tid for 80 weeks Placebo tid for 40 weeks then levodopa 100 tid for 40 week Primary outcome was between-group differences in change from baseline to week 80 on total UPDRS Verschuur et al. NEJM 2019 Results Verschuur et al. NEJM 2019 Conclusions . No difference Disease progression Rate of dyskinesia Levodopa-related dyskinesia . Levodopa treatment at 25/100 tid had no detrimental effect on patients with early PD Verschuur et al. NEJM 2019 Dopamine agonists Half Life in hours Pramipexole (Mirapex®) 8 hours (tid) Pramipexole ER 12 hours (1ce day) Ropinirole (Requip®) 6 hours (tid) Ropinirole XL 47 hours (1ce daily) Rotigotine patch (Neupro®) 5 hours: terminal half life Agonist efficacious as initial therapy for symptoms and to delay motor fluctuations ropinirole Rascol et al. NEJM 2000;342(20):1484-91 pramipexole Halloway et al. Arch Neurol 2004 Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease A 4-Year Randomized Controlled Trial Arch Neurol. 2004;61(7):1044-1053. doi:10.1001/archneur.61.7.1044 Halloway et al. Arch Neurol 2004 Dopaminergic agents: side effects . Levodopa > DA . Dopamine agonists > agonists levodopa Nausea Impulse control disorders Dyskinesia Excessive daytime sleepiness Motor fluctuations Hallucinations Dopamine Orthostatic hypotension dysregulation Pedal edema with erythema (addiction) PSG Arch Neurol 2004 Initial treatment Direct Dopamine Agonist vs levodopa . Dopamine agonists Less dyskinesia and motor fluctuations in the first 5 years with agonist More side effects . Levodopa Better efficacy Fewer side effects No evidence for neurotoxicity Fox et al. Move disord 2018 Hauser et al. Move Disord 2007 Katzenschlager R et al Neurology 2008 Shannon K. Nat Clin Pract 2008 Initial monotherapy with dopamine agonists is not superior to initial monotherapy with levodopa Levodopa Dopamine agonists Oertel W, Schulz J. J Neurochem 2016 Chaudhuri et al. Mov Disordr 2018 Chaudhuri et al. Mov Disord 2018 Risk factors • Dyskinesia . Motor fluctations • Lower age of onset Lower age of onset • Higher dose levodopa Higher dose levodopa • Treatment in North Higher UPDRS part II America more than North America > Europe Europe Female gender • Lower weight More severe disease • Female gender Olanow CW, Stocchi F. ov Disord 2018 Available preparations of carbidopa/levodopa . Immediate release (Sinemet ®) . Orally dissolving (Parcopa®) . Controlled release (Sinemet CR®) . Combination with entacapone (Stalevo®) . IR/CR (Rytary®) . Levodopa intestinal gel (Duopa ®) Available preparations of carbidopa levodopa . There does not appear to be an advantage of one preparation of carbidopa levodopa over another in early PD in delaying motor fluctuations Stride PD study (carbidopa levodopa with and without entacapone) IR carbidopa/ levodopa to CR Stocchi et al. Ann Neurol 2010 Koller WC et al. Neurology 1999 Extended release levodopa (IPX066, Rytary®, Impax) . Combines immediate release levodopa and extended release levodopa . Capsules containing beads of both formulations . Rapid onset of action (IR) with extended effects from controlled release (ER) . Doubles the duration of effect of regular levodopa . Tartaric acid incipient to promote absorption of levodopa in the more alkaline gut. Margolesky and Singer. Adv Neurol Disord 2018 Extended-release carbidopa-levodopa (IPX066) compared with immediate- release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial Caveat: Dose of levodopa was 45% higher in the IPX066 group Hauser et al, 2013 , Rytary ® : advantages-disadvantages Advantages Disadvantages . Fewer doses during the . More pills at a single dose day . Switching from IR to . change levodopa dose in Rytary smaller increments: More . Brand name so may be control of motor more expensive symptoms vs dyskinesia? . No known advantage . Nighttime dosing: less when initiating therapy, symptoms during night, only in patients with improvement in sleep motor fluctuations due to PD symptoms? IPX203: Impax and Amneal . Reformulation of IPX066 (Rytary®) . Longer acting (up to 7-8 hours) . Phase 2 results positive . Phase 3 study in 510 PD patients with motor fluctuations in progress Modi et al. Clin Neuropharm 2019 Levodopa gel intrajejunal infusions Duopa ® . Continuous release during the day . Delivered directly to small intestine where levodopa absorbed . No issues with slowed GI transit Levodopa‐carbidopaintestinal gel (Duopa®) in advanced Parkinson's disease 12‐month, open‐label results Fernandez et al. Mov Disord 2015 Amjad et al. Adv Ther 2019 Duopa® (levodopa gel) . Approximately $60,000 per year Coverage and reimbursement support . Complications in 47% 35% with device insertion 31 % abdominal pain 17% nausea 15% post-operative wound infection 40% levodopa associated peripheral neuropathy increased homocysteine; reduced vitamin B12; increased methylmalonic acid; and reduced vitamin B6. Fernandez et al. Mov Disord 2015 Romagnolo et al. Mov Dis Clin Prac 2018 In the pipeline: ND0612 (Neuroderm) . Continuous subcutaneous infusion of levodopa/carbidopa . Stable plasma levodopa levels . Reduction in off time without troublesome dyskinesia . Limited by dosing of levodopa (900 mg per day) Giladi et al. Mov Disord 2015 (abstract) Kieburtz et al. Mov Disord 2016 Olanow, Stocchi Mov Disord 2017 In the pipeline: The Accordion pill AP09004 (Intec Pharma) . Gastric retention capsule . Multiple layers combining immediate and slow release form of l-dopa . Plasma half-life of 5-7 hours . TID dosing . Phase 3 study underway comparing to IR levodopa . Open label extension Levodopa accordion pill Intecpharma.com 2018 Lewitt et al. Parkinsonism Rel Dis 2019 Prolong effect of levodopa . COMT inhibition . MAO B inhibition . Provides 1-2 hours of increased time with effective treatment when combined with levodopa Treatment of motor fluctuations MAO-B inhibition selegiline rasagiline safinamide Fox et al. Move Disord 2018 MAO B inhibitors . Selegiline Metabolized to l-amphetamine Mild reduction in OFF time for 1-1.5 hours Twice a day Extensive first pass metabolism . Rasagiline No amphetamine metabolites Once a day intake Reduced “off” time by 1.2 hours Golbe, Neurology 1989;8:1109-1111 Olanow CW et al. N Engl J Med 2009 Safinamide (Xadago®) Motor fluctuations (Newron Pharmaceuticals) . Water-soluble . Potent, highly selective reversible MAO-B inhibitor . Blocks voltage dependent Na and Ca channels . Reduces neuronal glutamate release Safinamide (Xadago®) FDA approved 3/2017 . Potent, highly selective reversible MAO-B inhibitor . Blocks voltage dependent Na and Ca channels . Reduces neuronal glutamate release . DB-PC-randomized . 549 fluctuating PD . Safinamide 100mg as tolerated “on” time without troublesome dyskinesia troublesome “on” time without . Daily “on” time at 24 weeks increased by 0.8 hours . Most frequent AE was modest increase in dyskinesia Schapira et al. JAMA neurol 2017 Treatment of motor fluctuations COMT inhibition
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • Summary of Drug Limitations Mary C
    RON DESANTIS GOVERNOR SUMMARY OF DRUG LIMITATIONS MARY C. MAYHEW SECRETARY **Medications listed in this document may or may not require a prior authorization. Please view the Preferred Drug List at: http://ahca.myflorida.com/Medicaid/Prescribed_Drug/pharm_thera/fmpdl.shtml** Summary of Drug Limitations Abilify (aripiprazole) 2mg, 5mg, 20mg, 30mg tablets Minimum age = 6; Maximum of 1 tablet per day Abilify (aripiprazole) 10mg, 15mg tablets Minimum age = 6; Maximum of 15mg per day for ages = 6 - 11; Maximum of 30mg per day for ages = 12-17 Maximum of 1 tablet per day Abilify (aripiprazole) Discmelt 10mg, 15mg tabs Minimum age = 6; Maximum of 15mg per day for ages = 6 - 11; Maximum of 30mg per day for ages = 12-17; Maximum of 2 tablets per day Abilify (aripiprazole) 1mg/ml solution Minimum age = 6; Maximum of 15ml per day for ages = 6 - 11; Maximum of 30ml per day for ages = 12-17; Maximum of 30ml per day for ages =/> 18 Abilify Maintena (aripiprazole) syringe/vial Minimum age = 18; Maximum of 1 syringe or vial every 28 days Absorica (isotretinoin) 10mg, 20mg, 25mg,30mg, 35mg, & Minimum age = 12 40mg capsules Abstral (fentanyl citrate) sublingual tablets Minimum age = 18; Maximum of 4 sublingual tablets per day Acanya (benzoyl peroxide/clindamycin)Gel, gel pump Minimum Age= 12 Accolate (zafirlukast) tablets Maximum of 3 tablets per day Aciphex (rabeprazole) 5mg, 10mg sprinkle capsules Minimum age = 1; Maximum age = 11; Maximum of 1 capsule per day Aciphex (rabeprazole) 20mg tablets Minimum age = 1; Maximum of 2 tablets per day Actemra (tocilizumab) 80mg/4ml, 200mg/10ml, Minimum age= 2 400mg/20ml Vials, & 162mg/0.9ml Syringe Actimmune (Interferon Gamma-1b) Maximum of 6ml every 28days Actiq (fentanyl citrate) Lozenges Minimum age = 18; Maximum of 4 lozenges per day Activella (estradiol/norethindrone) tablets Minimum age = 18 Updated 02/28/2019 1 RON DESANTIS GOVERNOR SUMMARY OF DRUG LIMITATIONS MARY C.
    [Show full text]
  • Safinamide: an Add-On Treatment for Managing Parkinson's Disease
    Journal name: Clinical Pharmacology: Advances and Applications Article Designation: REVIEW Year: 2018 Volume: 10 Clinical Pharmacology: Advances and Applications Dovepress Running head verso: Müller Running head recto: Safinamide for levodopa/carbidopa-treated PD patients with “off ” episodes open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CPAA.S137740 Open Access Full Text Article REVIEW Safinamide: an add-on treatment for managing Parkinson’s disease Thomas Müller Abstract: Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson’s disease. Intervals, characterized by reappearance of motor and Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, associated certain nonmotor symptoms, determine the end of good tolerability and efficacy of Germany oral levodopa therapy. These “OFF” states result from levodopa pharmacokinetics and disease progression-related deterioration of the central buffering capacity for fluctuations of dopamine levels. This review discusses safinamide as an add-on therapeutic agent in orally levodopa-treated patients with “OFF” phenomena. Safinamide provided beneficial effects on “OFF” symptoms in pivotal trials with doses of 50 or 100 mg once daily. Safinamide reversibly inhibits mono- amine oxidase B and declines abnormal glutamate release by modulation of potassium- and For personal use only. sodium ion channels. An ideal candidate for combination with safinamide is opicapone. This inhibitor of peripheral catechol-O-methyltransferase supports continuous brain delivery of levodopa and, thus, the continuous dopaminergic stimulation concept. Both compounds with their once-daily application and good tolerability may complement each other by reduction of necessary oral levodopa intakes and “OFF” times. Thus, a promising, future option will be combination of safinamide and opicapone in one formulation.
    [Show full text]
  • Opicapone for the Management of End-Of-Dose Motor Fluctuations in Patients with Parkinson’S Disease Treated with L-DOPA
    Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA Andrew J. Lees MD1, Joaquim Ferreira MD2, Olivier Rascol MD3, Heinz Reichmann MD,4 Fabrizio Stocchi MD,5 Eduardo Tolosa MD,6 Werner Poewe MD7 1. University College London, Reta Lila Weston Institute, London, UK 2. Hospital de Santa Maria, Centro de Estudos Egas Moniz, Lisbon, Portugal 3. Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC 1436, NS-Park/FCRIN network and NeuroToul COEN Center, INSERM, Toulouse University Hospital and Toulouse3 University, Toulouse, France 4. Department of Neurology, Technische Universitaet Dresden, Dresden, Germany 5. Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy 6. Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Spain. 7. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria Corresponding author Professor Andrew Lees University College London, Reta Lila Weston Institute, 1 Wakefield Street London WC1N 1PJ London, UK Email: [email protected] Direct telephone: + 44 20 7xxxxxxx Fax: +44 20 7xxxxxxx 1 Joaquim Ferreira [email protected] Olivier Rascol [email protected] Eduardo Tolosa [email protected] Fabrizio Stocchi [email protected] Heinz Reichmann [email protected] Werner Poewe [email protected] 2 Summary Introduction: Opicapone is a third generation, highly potent and effective catechol O‑methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L- DOPA therapy. Areas covered: In this review, we describe the preclinical and clinical development of opicapone.
    [Show full text]
  • 207145Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 MEDICAL REVIEW(S) Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) CLINICAL REVIEW Application Type NDA Application Number 207145 Priority or Standard Standard Submit Date 9/21/16 Received Date 9/21/16 PDUFA Goal Date 3/21/17 Division / Office DNP/ODE 1 Reviewer Name Leonard P. Kapcala, M.D. Review Completion Date 2/7/17 Established Name SAFINAMIDE (Proposed) Trade Name XADAGO Therapeutic Class Monoamine Oxidase B Inhibitor Applicant Newron Formulation(s) Tablet Dosing Regimen Once daily orally Indication(s) Treatment of signs and symptoms of Parkinson's disease Intended Population(s) Patients with early and advanced Parkinson's disease 1 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 5 1.4 Recommendations for Postmarket Requirements and Commitments ................ 5 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 5 2.1 Product Information (Based Upon Sponsor Summary) ....................................... 5 2.2 Other Relevant Background Information ...........................................................
    [Show full text]
  • 212489Orig1s000 SUMMARY REVIEW
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212489Orig1s000 SUMMARY REVIEW Gerald D. Podskalny, DO From Eric Bastings, MD Billy Dunn, MD Subject Joint Summary Review NDA/BLA # and Supplement# NDA 212489 Applicant Neurocrine Biosciences, Inc. Date of Submission 04/26/2019 PDUFA Goal Date 04/26/2020 Proprietary Name Ongentys Established or Proper Name Opicapone Dosage Form(s) 25-mg and 50-mg capsules Adjunctive treatment to levodopa/carbidopa in patients Applicant Proposed with Parkinson’s disease (PD) experiencing “off” Indication(s)/Population(s) episodes Applicant Proposed Dosing 50 mg orally once daily at bedtime. Regimen(s) Regulatory Action Approval Recommended Adjunctive treatment to levodopa/carbidopa in patients Indication(s)/Population(s) (if with Parkinson’s disease (PD) experiencing “off” applicable) episodes. Recommended Dosing 50 mg orally once daily at bedtime. Regimen(s) (if applicable) 1 Reference ID: 4597937 Reference ID: 4597937 1. Benefit-Risk Assessment Benefit-Risk Integrated Assessment Parkinson’s disease (PD) is the second most common neurodegenerative disease, with an estimated prevalence of 930,000 individuals in the United States. PD is caused by progressive loss of dopamine producing neurons in the substantia nigra located in the midbrain. The cardinal motor features of PD are bradykinesia, tremor, rigidity, and postural instability. As PD progresses, it causes increasing motor disability. Medications that replace or enhance the effects of dopamine, such as levodopa, treat the motor aspects of PD and remain the mainstay of treatment. About 5 years after starting treatment with levodopa, many patients develop motor fluctuations (dyskinesia and wearing-off). In advanced PD (approaching 10 years with PD and beyond), patients may develop cognitive impairment, neuropsychiatric symptoms (e.g., hallucinations and impulse control disorders) and impaired autonomic function (e.g., incontinence and orthostatic hypotension).
    [Show full text]
  • A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
    brain sciences Review A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice Javier Pagonabarraga 1,2,3,*, José Matías Arbelo 4,5 , Francisco Grandas 6,7, Maria-Rosario Luquin 8,9, Pablo Martínez Martín 10,11 , Mari Cruz Rodríguez-Oroz 12,13, Francesc Valldeoriola 14,15 and Jaime Kulisevsky 1,2,3,16,17 1 Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain; [email protected] 2 Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain 3 Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain 4 Movement Disorders Unit, Neurology Department, Hospital Universitario San Roque, 35001 Las Palmas, Spain; [email protected] 5 Department of Medicine, Universidad Fernando Pessoa-Canarias, 35450 Las Palmas, Spain 6 Movement Disorders Unit-CSUR, Neurology Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; [email protected] 7 Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain 8 Movement Disorders Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain; [email protected] 9 Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain 10 Instituto de Salud Carlos III, 28029 Madrid, Spain; [email protected] 11 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain 12 Neurology and Neuroscience Unit, Clínica Universidad de Navarra (CUN), 31008Pamplona,
    [Show full text]
  • Opicapone Capsules for the Treatment of Parkinsons Disease (Pd) in Adult Patients Recommended for Restricted Use (Amber Initiation)
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) OPICAPONE CAPSULES FOR THE TREATMENT OF PARKINSONS DISEASE (PD) IN ADULT PATIENTS RECOMMENDED FOR RESTRICTED USE (AMBER INITIATION) Name: generic What it is Indication Date Decision NICE / SMC (trade) decision status Guidance last revised Opicapone 50mg Peripheral, Licensed as adjunctive October 2019 Final NICE TA: not hard capsules selective and therapy to available ® (Ongentys ) reversible catechol- preparations of NICE guidance 0-methyltransferase levodopa/ DOPA for Parkinson’s (COMT) inhibitor decarboxylase disease in adults inhibitors in adult (NG71) patients with SMC not Parkinson's disease recommended and end-of-dose motor AWMSG fluctuations who recommended cannot be stabilised on those combinations HMMC recommendation: Opicapone 50mg capsules, within licensed indications, is recommended for restricted use as AMBER initiation as a second line COMT inhibitor in adult patients with PD with end-of-dose motor fluctuations who are intolerant of entacapone and where the next step of treatment would be the non-oral treatment options or tolcapone. Background Information: Opicapone is the third COMT inhibitor licensed in the UK with the recommended dose of 50 mg as an adjunct to levodopa/DDCI inhibitors. It should be taken once-daily at bedtime, at least one hour before or after levodopa combinations. In certain patients, this may enable a simplified drug regimen which may potentially improve compliance. Some patients taking a complicated PD drug regimen may find it easier to add a single tablet such as opicapone and keep their familiar levodopa doses over the day. In contrast, entacapone has to be taken with each levodopa dose, which may be up to 10 times daily.
    [Show full text]
  • Tolcapone Shared Care Guideline
    Using a printed guideline? Always check you are using the most up to date version. See www.ipnsm.hscni.net Tolcapone Neurology shared care guideline Specialist details Patient identifier Name: Location: Tel: Date: Introduction Licensed indications: Tolcapone is indicated in combination with levodopa/ benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyl transferase (COMT) inhibitors. Adult dosage and administration 100mg three times a day, leave 6 hours between each dose; maximum dose is 200mg three times a day in exceptional circumstances. The first daily dose should be taken at the same time as the levodopa with dopa-carboxylase inhibitor. Patients on higher doses of levodopa (> 600mg daily) or those who had moderate or severe dyskinesia before beginning treatment may require a levodopa dose reduction (specialist should advise). Available as: 100mg tablets Hospital specialist responsibilities Assess patient’s suitability for treatment with tolcapone. Assess patient's current repeat medications for potential significant interactions with the new treatment and discuss with GP if any concerns. Agree shared care with patient’s GP. Provide patient/carer with relevant written information on use, side-effects and need for monitoring of medication. In particular, patients should be informed of the risks of impulse control disorders1 and liver injury2 and advised to seek medical advice immediately. Provide shared care monitoring record booklet and record baseline tests. Baseline tests: LFT, U&E Review results of safety monitoring and request additional tests as required. Monitor disease response to treatment and need to continue therapy – tolcapone should be discontinued if substantial clinical benefits are not seen within 3 weeks of initiation of treatment regardless of dose.
    [Show full text]
  • Parkinson's Disease with End-Of-Dose Motor Fluctuations: Opicapone
    pat hways Parkinson’s disease with end-of-dose motor fluctuations: opicapone Evidence summary Published: 21 March 2017 nice.org.uk/guidance/es9 Key points The content of this evidence summary was up-to-date in March 2017. See summaries of product characteristics (SPCs), British national formulary (BNF), or the MHRA or NICE websites for up-to-date information. Regulatory status: New medicine. Opicapone is a catechol-O-methyl transferase (COMT) inhibitor. It received a European marketing authorisation in June 2016 and was launched in the UK in October 2016. It is licensed for adjuvant therapy to preparations of levodopa/DOPA decarboxylase inhibitor (DDCI) in adults with Parkinson's disease who are experiencing end-of-dose motor fluctuations and cannot be stabilised on those combinations. Overview This evidence summary reviewed 1 randomised placebo- and active-controlled trial in people with Parkinson's disease of at least 3-year duration, who were taking a stable dose of levodopa and experiencing end-of-dose motor fluctuations. Most participants were also taking other arkinsonP 's disease medicines, most commonly a dopamine agonist. There are limited data on the use of opicapone as a first choice adjunct therapy to levodopa. The main clinical benefits of opicapone 50 mg up to 15 weeks were reduced off time of 60.8 minutes and an increase in on time without troublesome dyskinesia of 62.6 minutes, © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 31 Parkinson’s disease with end-of-dose motor fluctuations: opicapone (ES9) compared with placebo.
    [Show full text]
  • Therapeutic Drug Guidelines for ATCS
    Revision #17 Date: 12-16-2016 Check with FAA flight surgeon to verify that this is the most current revision before using. THERAPEUTIC DRUG GUIDELINES FOR AIR TRAFFIC CONTROL SPECIALISTS Revision #17 Date: 12-16-2016 Check with FAA flight surgeon to verify that this is the most current revision before using. REVISION HISTORY Rev Description of Change Effective Date Posted changes to Accutane and Byetta; clarified nitrates and 1 08-15-2007 anticoagulation; deleted Zelnorm; added entacapone and Chantix 2 Added title page and Revision History page 08-16-2007 On page 3: updated Collective Bargaining Agreement reference and 3 08-29-2007 clarified that this document may be given to ATCSs 4 Clarified use of Optivar - do not instill in the eyes while on duty 08-31-2007 Corrected policy on mefloquine [Lariam]; added atovaquone/proguanil 5 10-05-2007 rMalaronel 6 Added Januvia 10-10-2007 7 Added Cialis 12-04-2007 8 Added aliskiren (Tekturna) 03-03-2008 9 Added mesalamine, including the various brand names 03-05-2008 10 Clarified that insulin pump is acceptable method of insulin delivery 05-19-2008 11 Updated policy on Chantix - it is not aeromedically acceptable 05-21-2008 12 Added levocetirizine (Xyzal) 06-02-2008 Clarified that neither form of oxybutynin (Ditropan and DitropanXL), is 13 05-15-2009 allowed because both can cause sedation similar to Benadryl 14 Article 66, Section 14 (NATCA CBA) annual review 06-30-2011 Corrected dextromethorphan - it is not acceptable due to adverse side 15 07-24-2013 effects. Article 66, Section 14 (NATCA CBA) annual review 16 Updated References; updated overactive bladder medications to indicate all are not acceptable due to new FDA warnings/precautions about 07-31-2013 adverse central nervous system effects including somnolence Revision #17 Date: 12-16-2016 Check with FAA flight surgeon to verify that this is the most current revision before using.
    [Show full text]
  • TASMAR* (Tolcapone) RATIONALE for INCLUSION in PA PROGRAM
    TASMAR* (tolcapone) * Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication. RATIONALE FOR INCLUSION IN PA PROGRAM Background Tasmar (tolcapone) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). Tolcapone is thought to work by inhibiting COMT and altering the plasma pharmacokinetics of levodopa. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. These sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson’s disease (1). Regulatory Status FDA-approved indications: Tasmar is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (1). Tasmar has a boxed warning regarding liver failure. Tasmar therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution. Tasmar should be discontinued if SGPT/ALT or SGOT/AST levels exceed 2 times the upper limit of normal or if clinical signs and symptoms suggest onset of hepatic dysfunction (1). Because of the risk of potentially fatal, acute fulminant liver failure, Tasmar should ordinarily be used in patients with Parkinson’s disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (1).
    [Show full text]